Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Pritelivir successful in topical Ph.1
AiCuris' Anti-HSV Drug Pritelivir achieves primary endpoint in Phase 1 study
Pritelivir ointment did not show any cumulative irritation potential. This phase 1 trial is part of a second development program for Pritelivir.
Pritelivir: Two Recent Publications
Publications Confirm the Potency of the Novel Anti-HSV Drug
Clinical data published in the peer-reviewed “Journal of Infectious Diseases”.... / Phase II data were used for the development of a mathematical model- published in "Science Translational Medicine”
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.